Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil

Annals of Oncology

Volumn 17, Issue 2, 2006, Pages 252-258

  Pfeiffer, Per ^a   Sorbye H ^b   Ehrsson, H ^c   Fokstuen, T ^c   Mortensen, J P ^d   Baltesgard, L ^e   Tveit, K M ^f   Ogreid D ^g   Starkhammar, H ^h   Wallin, I ^c   Qvortrup, C ^a   Glimelius, B ^c,i  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d LILLEBAELT HOSPITAL   (Denmark)

^e UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^f ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^g STAVANGER UNIVERSITY HOSPITAL   (Norway)

^h LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

ⁱ UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Capecitabine; Colorectal cancer; Oxaliplatin; Pharmacokinetics; Short time infusion

Indexed keywords

CAPECITABINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; XELOX;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DYSESTHESIA; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; INJECTION SITE PAIN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 31544438341     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj060     Document Type: Article

References (31)

1. Ragnhammar P, Hafstrom LO, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001; 40: 282-308.
2. Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412.
3. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet. 2000; 355: 1041-1047.
4. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. New Engl J Med 2000; 343: 905-914.
5. Kohne C, Van Cutsem E, Wils J et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of EORTC GI group study 40986. ASCO GI Cancers Symposium 2004; Abstr 217.
6. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomised trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
7. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
8. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
9. Andre T, Bensmaine MA, Louvet C et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999; 17: 3560-3568.
10. De Gramont A, Vignoud J, Tournigand C et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33: 214-219.
11. Schüller J, Cassidy J, Dumont E et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 291-297.
12. Borner MM, Dietrich D, Stupp R et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002; 20: 1759-1766.
13. Diaz-Rubio E, Evans TRJ, Tabernero J et al. Capecitabine (Xeloda) in combination with oxaliplatin: A phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol 2002; 13: 558-565.
14. Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084-2091.
15. Pfeiffer P, Hahn P, Jensen HA. Short-time infusion of oxaliplatin (Eloxatin®) in combination with capecitabine (Xeloda®) in patients with advanced colorectal cancer. Acta Oncol 2003; 42: 832-835.
16. Glimelius B, Ristamaki R, Kjaer M et al. Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Ann Oncol 2002; 13: 1868-1873.
17. Jakobsen A, Berglund A, Glimelius B et al. Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer. Acta Oncol 2002; 41: 525-531.
18. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
19. Kohne CH, Cunningham D, Di Costanzo F et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-317.
20. Ehrsson H, Wallin I. Liquid chromatographic determination of oxaliplatin in blood using post-column derivatization in a microwave field followed by photometric detection. J Chromatogr B 2003; 795: 291-294.
21. Boxenbaum HG, Riegelman S, Elashoff RM. Statistical estimations in pharmacokinetics. J Pharmacokin Biopharm 1974; 2: 123-148.
22. Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Ooncol 2003; 21: 2059-2069.
23. Grothey A, Sargent D, Goldberg RM, Schmoll H-J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214.
24. Ramanathan RK, Clark JW, Kemeny NE et al. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol 2003; 21: 2904-2911.
25. Cassidy J, Twelves C, Van Cutsem E et al. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566-575.
26. Sørbye H, Glimelius B, Berglund Å et al. Multicenter phase II study of nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004; 22: 31-38.
27. Ehrsson H, Wallin I, Yachnin J. Pharmacokinetics of oxaliplatin in humans. Med Oncol 2002; 19: 261-265.
28. Delord JP, Umlil A, Guimbaud R et al. Population pharmacokinetics of oxaliplatin. Cancer Chemother Pharmacol 2003; 51: 127-131.
29. Reece PA, Stafford I, Davy M et al. Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer. Cancer Chemother Pharmacol 1989; 24: 256-260.
30. Graham MA, Lockwood GF, Greenslade D et al. Clinical pharmacokinetics of oxaliplatin: A critical review. Clin Cancer Res 2000; 6: 1205-1218.
31. Kizu R, Higashi S, Kidani Y, Miyazaki M. Pharmacokinetics of (1R,2R-diaminocyclohexane) oxalatoplatinum (II) in comparison with cisplatin following a single intravenous injection in rabbits. Cancer Chemother Pharmacol 1993; 31: 475-480.